Caribou Biosciences, Inc. (CRBU)
0.3046
-0.01
(-1.90%)
USD |
NASDAQ |
Nov 20, 10:21
Caribou Biosciences Cash from Operations (Quarterly) : -22.52M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -22.52M |
| June 30, 2026 | -22.79M |
| March 31, 2026 | -26.98M |
| December 31, 2025 | -20.82M |
| September 30, 2025 | -25.18M |
| June 30, 2025 | -28.26M |
| March 31, 2025 | -36.72M |
| December 31, 2024 | -35.47M |
| September 30, 2024 | -32.66M |
| June 30, 2024 | -32.87M |
| March 31, 2024 | -37.20M |
| December 31, 2023 | -21.38M |
| September 30, 2023 | -28.79M |
| June 30, 2023 | -15.18M |
| Date | Value |
|---|---|
| March 31, 2023 | -27.94M |
| December 31, 2022 | -25.04M |
| September 30, 2022 | -22.38M |
| June 30, 2022 | -21.87M |
| March 31, 2022 | -21.67M |
| December 31, 2021 | -21.39M |
| September 30, 2021 | -14.97M |
| June 30, 2021 | -16.48M |
| March 31, 2021 | 20.31M |
| December 31, 2020 | -8.076M |
| September 30, 2020 | -8.691M |
| June 30, 2020 | -7.205M |
| March 31, 2020 | -9.243M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Anavex Life Sciences Corp. | -9.096M |
| Vaxcyte, Inc. | -224.08M |
| Foghorn Therapeutics, Inc. | -18.24M |
| Bolt Biotherapeutics, Inc. | -3.078M |
| Connect Biopharma Holdings Ltd. | -12.31M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 19.39M |
| Cash from Financing (Quarterly) | 2.989M |
| Free Cash Flow | -92.99M |
| Free Cash Flow Per Share (Quarterly) | -0.2096 |
| Free Cash Flow to Equity (Quarterly) | -22.22M |
| Free Cash Flow to Firm (Quarterly) | -22.54M |
| Free Cash Flow Yield | -282.6% |